Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 14, 2025
Daily News
July 14, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Toho, Teijin, and Itochu to Jointly Build Regenerative Medicine Ecosystem
July 14, 2025
- Solasia Invests in Sweden’s Isofol as Colorectal Cancer Trials Resume
July 14, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
- Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
July 14, 2025
- More Firms Signal Interest in Meiji-Daito Consortium to Revamp Generic Production
July 14, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…